Filing Overview
Phathom Pharmaceuticals, Inc. filed a Form 8-K dated July 13, 2020, under Item 5.02 and Item 9.01. The filing reports a change in the company’s principal financial and accounting officer and related compensation arrangements. It does not provide quarterly or annual financial results.
Business Context and Reporting Period
Phathom is a pharmaceutical company whose development activities include vonoprazan. The filing is current as of July 13, 2020. Todd Branning, age 50, was appointed Chief Financial Officer effective that date and replaced David Socks as the company’s principal financial and accounting officer for SEC filings.
Mr. Socks will remain an employee and strategic advisor and will continue serving on the company’s board of directors.
Financial Metrics and Liquidity
- Revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity, and other operating metrics are not reported in this filing.
- The filing text does not provide a clear value for any change in financial outlook or funding runway.
Material Changes and Compensation Arrangements
- Mr. Branning previously served as CFO of Amneal Pharmaceuticals from January 2019 through March 2020 and held prior financial leadership positions at Teva, Allergan, PricewaterhouseCoopers, PPG Industries, and Merck.
- His initial annual base salary is $425,000, with a target annual bonus equal to 40% of base salary. His 2020 bonus will be prorated based on his employment period.
- Upon joining, he will receive options to purchase 85,000 shares under the 2019 Incentive Award Plan. The options have a 10-year term, an exercise price equal to the company’s stock fair market value on the grant date, and four-year vesting with 25% vesting after one year and the remainder vesting monthly over three years.
- He will also receive 10,000 performance-based share units. The PSUs are expected to vest upon FDA approval of vonoprazan for erosive esophagitis, assuming prior FDA approval for H. pylori.
Severance, Outlook, and Risks
- For termination without cause or resignation for good reason outside a change-in-control period, Mr. Branning is eligible for nine months of base-salary continuation, specified bonus payments, COBRA premium payments during the applicable period, and acceleration of equity awards that would have vested during the severance period.
- During the period beginning three months before and ending 24 months after a change in control, the severance period increases to 12 months, the applicable bonus treatment is enhanced, and outstanding unvested equity awards become fully vested upon the later of the effective release date or the change-in-control date.
- Severance benefits are subject to conditions including execution of a release of claims, return of company property, compliance with post-termination obligations, and resignation from company positions.
- The PSU award is contingent on specified FDA approvals, creating execution and regulatory risk. The filing provides no broader corporate guidance or financial forecast.
Investor Verification Points
- Confirm the effective date and scope of Mr. Branning’s authority as principal financial and accounting officer.
- Review Exhibit 10.1 for the complete employment, severance, option, and PSU terms.
- Monitor FDA progress for vonoprazan in H. pylori and erosive esophagitis, which affects the PSU vesting condition.
- Review subsequent filings for equity grants, compensation expense, changes in management responsibilities, and the company’s financial condition, since this 8-K contains no financial statements or liquidity data.